A heart drug lowered inflammation exactly as planned - and failed anyway

A drug that worked and failed at the same time

This week a heart drug did everything it was designed to do, and still failed.

Novo Nordisk’s ziltivekimab blocks IL-6, a protein that switches on inflammation. In a large trial it lowered inflammation exactly as planned. Yet it did not prevent a single extra heart attack or stroke. And more people taking it caught serious infections than people taking a placebo.

Read that last part again. The drug turned down inflammation, and the cost that came back was infection. That is not a side effect to engineer away. It is the whole shape of the thing.

One system, two opposite jobs

Inflammation is not a disease. It is your defense.

In its sharp, short form it is what fights off an infection and heals a wound. Without it, an ordinary germ would kill you in days. The redness around a cut, the fever with a flu - that is the system working.

But the same response, running low and long for years, is one of the biggest drivers of the diseases of age: heart disease, diabetes, cancer, Alzheimer’s. One machinery. One helps. One harms. They are not two systems you can separate. They are the same system doing its job in two different tempos.

So when a drug quiets inflammation, it quiets both faces at once. You cannot keep the guard and dismiss the guard.

The trade-off is built in, not broken in

Biologists have a name for this: antagonistic pleiotropy. It means one trait, one gene, one mechanism that helps in one way and costs in another.

Why would nature build that in? Because evolution cares about surviving long enough to have children. A fierce inflammatory response keeps a young body alive through infection and injury - a huge early benefit. The cost, chronic disease decades later, arrives long after children are grown. Selection barely feels it.

So the trade-off is not a flaw waiting for a fix. It is the deal that got us here. The good and the bad ride on the same gene, and they were kept together because, on balance, keeping them paid.

The dial you cannot cleanly turn

This is why the ziltivekimab result was almost predictable in hindsight.

You reach for the inflammation dial hoping to turn down only the heart damage. But there is one dial, not two. Turn it down and the infection defense drops with it - which is exactly what the trial saw. And the heart benefit you were chasing did not even arrive, because heart disease has more than one driver, and inflammation may not be the master switch anyone hoped.

No clean win. A cost you did not want, and the prize still out of reach.

You have met this before

Once you see the pattern, it is everywhere in the body.

The sickle-cell gene: one copy protects against malaria, two copies cause a painful disease. Cellular senescence: a cell freezes so it cannot become a tumor, but the signals it leaks help other cancers spread and drive aging. Blood clotting: the same machinery that seals a cut can block an artery and cause a stroke. The stress response that saves you in a real emergency wears the body down when it never shuts off.

None of these are bugs. Each is a bargain the body struck, useful on one side and costly on the other.

The body is a web of bargains, not a machine with bad parts

It is tempting to picture the body as a machine with a few faulty parts we can swap out or switch off. The trade-off says otherwise.

We are inside this, all of us. Every one of us carries these bargains in our own cells - the defense that ages us, the clot that could save us or kill us. A medicine cabinet is not a set of fixes; it is a set of new bargains, each with its own far side.

That should make us slower to trust any promise to remove a downside without a cost. The supplement that only helps. The drug with no trade. The one weird trick. In a system this woven together, the honest question is never “how do I switch this off,” but “what do I give up if I do.”